Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. more
Time Frame | LCTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 10.28% | -2.12% | -3% |
1-Month Return | -13% | -3.42% | -0.73% |
3-Month Return | -40.64% | -11.13% | 2.87% |
6-Month Return | -37.6% | -5.74% | 7.17% |
1-Year Return | -44.75% | 3.97% | 25.31% |
3-Year Return | -78.29% | 1.05% | 28.38% |
5-Year Return | -6.17% | 34.37% | 81.89% |
10-Year Return | -82.04% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.48M | 773.00K | 3.90M | 14.70M | 8.95M | [{"date":"2019-12-31","value":10.05,"profit":true},{"date":"2020-12-31","value":5.26,"profit":true},{"date":"2021-12-31","value":26.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":60.84,"profit":true}] |
Cost of Revenue | 412.00K | 385.00K | 1.43M | 728.00K | 671.00K | [{"date":"2019-12-31","value":28.89,"profit":true},{"date":"2020-12-31","value":27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":51.05,"profit":true},{"date":"2023-12-31","value":47.05,"profit":true}] |
Gross Profit | 1.07M | 388.00K | 2.47M | 13.97M | 8.27M | [{"date":"2019-12-31","value":7.63,"profit":true},{"date":"2020-12-31","value":2.78,"profit":true},{"date":"2021-12-31","value":17.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.21,"profit":true}] |
Gross Margin | 72.12% | 50.19% | 63.40% | 95.05% | 92.50% | [{"date":"2019-12-31","value":75.88,"profit":true},{"date":"2020-12-31","value":52.81,"profit":true},{"date":"2021-12-31","value":66.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.32,"profit":true}] |
Operating Expenses | 39.94M | 26.84M | 51.68M | 36.49M | 33.01M | [{"date":"2019-12-31","value":77.29,"profit":true},{"date":"2020-12-31","value":51.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.62,"profit":true},{"date":"2023-12-31","value":63.87,"profit":true}] |
Operating Income | (38.88M) | (26.45M) | (49.21M) | (22.52M) | (24.73M) | [{"date":"2019-12-31","value":-3887600000,"profit":false},{"date":"2020-12-31","value":-2644700000,"profit":false},{"date":"2021-12-31","value":-4921100000,"profit":false},{"date":"2022-12-31","value":-2252000000,"profit":false},{"date":"2023-12-31","value":-2473300000,"profit":false}] |
Total Non-Operating Income/Expense | 21.33M | 5.56M | 5.94M | (2.46M) | 3.08M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":26.08,"profit":true},{"date":"2021-12-31","value":27.87,"profit":true},{"date":"2022-12-31","value":-11.55,"profit":false},{"date":"2023-12-31","value":14.44,"profit":true}] |
Pre-Tax Income | (19.23M) | (21.92M) | (43.27M) | (25.81M) | (23.28M) | [{"date":"2019-12-31","value":-1923400000,"profit":false},{"date":"2020-12-31","value":-2192400000,"profit":false},{"date":"2021-12-31","value":-4327000000,"profit":false},{"date":"2022-12-31","value":-2581200000,"profit":false},{"date":"2023-12-31","value":-2328200000,"profit":false}] |
Income Taxes | (7.41M) | (1.24M) | (4.71M) | 541.00K | (1.80M) | [{"date":"2019-12-31","value":-1369.13,"profit":false},{"date":"2020-12-31","value":-229.02,"profit":false},{"date":"2021-12-31","value":-869.87,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-333.27,"profit":false}] |
Income After Taxes | (11.83M) | (20.68M) | (38.56M) | (26.35M) | (21.48M) | [{"date":"2019-12-31","value":-1182700000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-3856400000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2147900000,"profit":false}] |
Income From Continuous Operations | (26.64M) | (20.68M) | (43.27M) | (26.35M) | (21.48M) | [{"date":"2019-12-31","value":-2664100000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-4327000000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2147900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (11.83M) | (20.68M) | (38.56M) | (26.35M) | (21.49M) | [{"date":"2019-12-31","value":-1182700000,"profit":false},{"date":"2020-12-31","value":-2068500000,"profit":false},{"date":"2021-12-31","value":-3856400000,"profit":false},{"date":"2022-12-31","value":-2635300000,"profit":false},{"date":"2023-12-31","value":-2148600000,"profit":false}] |
EPS (Diluted) | (0.05) | (0.14) | (0.26) | (0.15) | (0.13) | [{"date":"2019-12-31","value":-5,"profit":false},{"date":"2020-12-31","value":-14,"profit":false},{"date":"2021-12-31","value":-26,"profit":false},{"date":"2022-12-31","value":-15,"profit":false},{"date":"2023-12-31","value":-13,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LCTX | |
---|---|
Cash Ratio | 2.36 |
Current Ratio | 2.48 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LCTX | |
---|---|
ROA (LTM) | -12.86% |
ROE (LTM) | -35.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LCTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.33 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.67 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LCTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 19.88 |
P/B | 1.86 |
Price/FCF | NM |
EV/R | 10.67 |
EV/Ebitda | NM |
Lineage Cell Therapeutics Inc (LCTX) share price today is $0.558
Yes, Indians can buy shares of Lineage Cell Therapeutics Inc (LCTX) on Vested. To buy Lineage Cell Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LCTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Lineage Cell Therapeutics Inc (LCTX) via the Vested app. You can start investing in Lineage Cell Therapeutics Inc (LCTX) with a minimum investment of $1.
You can invest in shares of Lineage Cell Therapeutics Inc (LCTX) via Vested in three simple steps:
The 52-week high price of Lineage Cell Therapeutics Inc (LCTX) is $1.61. The 52-week low price of Lineage Cell Therapeutics Inc (LCTX) is $0.48.
The price-to-earnings (P/E) ratio of Lineage Cell Therapeutics Inc (LCTX) is
The price-to-book (P/B) ratio of Lineage Cell Therapeutics Inc (LCTX) is 1.86
The dividend yield of Lineage Cell Therapeutics Inc (LCTX) is 0.00%
The market capitalization of Lineage Cell Therapeutics Inc (LCTX) is $110.65M
The stock symbol (or ticker) of Lineage Cell Therapeutics Inc is LCTX